Promising Cancer Vaccine for Glioblastoma Therapy: A Focus on mRNA Vaccine
Cancer Medicine, Volume 14, Issue 18, September 2025.ABSTRACT Background Glioblastoma (GBM) is an aggressive primary brain tumor with poor prognosis and low survival rates. Standard treatments, such as surgery and radiotherapy, are limited by tumor infiltration and resistance. To review current vaccine strategies for GBM, including peptide, virotherapy, cell‐based, and genetic vaccines, with a focus on ...
Sama Barati +5 more
wiley +1 more source
Two Decades of Optogenetic Tools: A Retrospective and a Look Ahead
Advanced Genetics, Volume 6, Issue 3, September 2025.Optogenetics provides up to millisecond scale, cell type‐specific control of biology using light‐sensitive proteins. This review chronicles two decades of tool development, from microbial rhodopsins and photoactivated enzymes to allosteric switches, surveys broad applications in neuroscience, molecular and cell biology, cardiology, immunology, and ...
Xiao Duan, Mo Zhu, Shiqiang Gao
wiley +1 more source
Cancer Innovation, Volume 4, Issue 4, August 2025.Glioblastoma (GBM) remains a highly malignant brain tumor with limited treatment efficacy, driving the need for innovative cellular immune theranostic strategies that integrate diagnostic and therapeutic approaches. Recent advances in cellular immunotherapy for GBM include chimeric antigen receptor (CAR)‐T/NK cells, macrophage‐based therapies ...
Ying Gong +14 more
wiley +1 more source
Literature review: Virus and cancer [PDF]
, 2017 Traballo fin de grao (UDC.CIE). Bioloxía. Curso 2016/2017[Abstract] Cancer is one of the main causes of global mortality, and even though it is considered to be a non-communicable disease, several infectious agents have been found to contribute to ...
Carreira Santos, Sofía
core
Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy [PDF]
, 2016 Ovarian cancer accounts for >140 000 deaths globally each year. Typically, disease is asymptomatic until an advanced, incurable stage. Although response to cytotoxic chemotherapy is frequently observed, resistance to conventional platinum-based therapies
A Hemminki +40 more
core +1 more source
Targeting oncogenic fusion-driven NUT carcinoma with CRISPR-Cas9 genome editing
Molecular Therapy: OncologyNUT carcinoma (NC) is a highly aggressive malignancy characterized by an oncogenic fusion gene incorporating the NUTM1 gene. To date, no established treatment options exist.
Maxim F. Carle +7 more
doaj +1 more source
Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy [PDF]
, 2014 Despite initial promising results, the success of clinical trials testing oncolytic viruses in glioblastoma patients has been limited. Innate immunity appears to be one among several barriers against successful viral oncolysis.
Alvarez-Breckenridge, Christopher A. +3 more
core +1 more source
Figure S2 from Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models [PDF]
, 2023 Dipongkor Saha +5 more
openalex +1 more source
The Role of PIWI‐Interacting RNA in Urologic Carcinoma and Its Clinical Implications
Cancer Reports, Volume 8, Issue 8, August 2025.ABSTRACT Piwi‐interacting RNA (piRNA) represents a class of small non‐coding RNA molecules, typically ranging in length from 18 to 35 nucleotides. These molecules are critically involved in the preservation of genomic integrity and the regulation of protein translation processes.
Jiajia Cai +9 more
wiley +1 more source
HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy [PDF]
, 2014 Several clinical trials have shown that oncolytic herpes simplex virus type 1 (oHSV-1) can be safely administered to patients. However, virus replication in tumor tissue has generally not been monitored in these oHSV clinical trials, and the data suggest
Decklever, T D +4 more
core +1 more source